J Biol Chem, Vol. 274, Issue 33, 23633-23641, August 13, 1999
Specific Contributions of the Small GTPases Rho, Rac, and
Cdc42 to Dbl Transformation*
Rui
Lin
,
Richard A.
Cerione
, and
Danny
Manor§¶
From the
Department of Molecular Medicine, Veterinary
Medical Center and the § Division of Nutritional Sciences,
Cornell University, Ithaca, New York 14853
 |
ABSTRACT |
Dbl is a representative prototype of a growing
family of oncogene products that contain the Dbl homology/pleckstrin
homology elements in their primary structures and are associated with a variety of neoplastic pathologies. Members of the Dbl family have been
shown to function as physiological activators (guanine nucleotide exchange factors) of the Rho-like small GTPases. Although the expression of GTPase-defective versions of Rho proteins has been shown
to induce a transformed phenotype under different conditions, their
transformation capacity has been typically weak and incomplete relative
to that exhibited by dbl-like oncogenes. Moreover, in some
cases (e.g. NIH3T3 fibroblasts), expression of
GTPase-defective Cdc42 results in growth inhibition. Thus, in
attempting to reconstitute dbl-induced transformation of
NIH3T3 fibroblasts, we have generated spontaneously activated
("fast-cycling") mutants of Cdc42, Rac1, and RhoA that mimic the
functional effects of activation by the Dbl oncoprotein. When stably
expressed in NIH3T3 cells, all three mutants caused the loss of serum
dependence and showed increased saturation density. Furthermore, all
three stable cell lines were tumorigenic when injected into nude mice.
Our data demonstrate that all three Dbl targets need to be activated to
promote the full complement of Dbl effects. More importantly,
activation of each of these GTP-binding proteins contributes to a
different and distinct facet of cellular transformation.
 |
INTRODUCTION |
The dbl oncogene was first identified by transfection
of fibroblasts with DNA from a human diffuse-B-cell lymphoma (1, 2).
Since then, over 15 different oncogene products have been described
that bear strong sequence and functional homology to the original Dbl
protein (3, 4). Operationally, Dbl family members have been defined as
proteins that contain the tandem arrangement of a pleckstrin homology
domain adjacent to a unique domain (approximately 180 amino acids)
found only in members of this family, and hence termed the Dbl homology
domain. Many of these proteins possess high oncogenic activity, and
indeed, most of the Dbl family members were initially found in gene
transfer experiments through their ability to potently transform
fibroblasts. Oncogenic activation of these cellular proto-oncogenes
often occurs by a specific mutation or a chromosomal rearrangement
event, which results in continuous, unregulated activity of the mutated proteins.
To date, most Dbl family members have been shown to serve as
activators, or guanine nucleotide exchange factors
(GEFs),1 for Rho-like
proteins (i.e. Cdc42, Rac, and Rho) (3). Like all
GTP-binding proteins, members of the Rho subfamily function as binary
molecular switches that are "on" in the GTP-bound state and
"off" in the GDP-bound state (5-7). Deactivation (transition from
the GTP to the GDP state) is achieved by their intrinsic GTP hydrolytic
capability, which is further stimulated by GTPase activating proteins
(GAPs). Activation of the GTP-binding proteins occurs in response to a
variety of stimuli (such as cell cycle progression and growth
factor/cytokine stimulation) and is mediated by GEFs, which stimulate
the dissociation of bound GDP. GTP then rebinds, thus triggering the
conformational change that leads to the activated state of the molecule.
Because nucleotide exchange is the only biochemical activity
demonstrated by Dbl proteins, and because transformation and exchange
activities share common structure/function features (8), it has been
assumed that the activation of Rho proteins is the basis for the
oncogenic activity demonstrated by Dbl proteins. A logical extension of
this reasoning is that activated alleles of Rho proteins should be
transforming when introduced into cells. Such dominant-positive
reagents are typically generated by mutations of residues that are
critical for GTP hydrolysis, thus rendering the protein
GTPase-defective. When introduced into a cell, the GTPase-defective
GTP-binding protein elicits a persistent stimulation of its signaling
cascade, resulting in an exaggerated phenotype that directly
demonstrates its involvement in a particular pathway. This is
exemplified in the case of Ras, in which expression of either the
Ras(G12V) or Ras(Q61L) GTPase-defective mutant is oncogenic (9), and
indeed, such mutations are found in a significant fraction of human
tumors (10).
For members of the Dbl family, elucidation of their transformation
mechanism has not been straightforward. Some oncogenic activity has
been observed upon expression of the GTPase-defective proteins
RhoA(Q63L), Rac1(G12V), and Cdc42(G12V) in fibroblasts and in
immunocompromised mice (11-17). Furthermore, dominant-negative mutants
of these proteins were shown to block Ras-induced transformation, indicating their critical role in proliferative signaling pathways (12-15). However, the oncogenic capacity of these proteins has been
typically incomplete and weak. Moreover, stable overexpression of
GTPase-defective Rho proteins has tended to be difficult. In particular, we have consistently found that significant overexpression of the GTPase-defective alleles (i.e. G12V or Q61L) of Cdc42
in NIH3T3 cells actually has detrimental effects on cell growth. This
has prompted us to consider the idea that for proper signaling, Cdc42
must undergo a complete cycle of GTP binding and hydrolysis.
We have therefore used an alternative scheme for activation of
ectopically expressed GTPases; rather than a mutation that blocks GTP
hydrolysis, we have generated mutants that possess enhanced intrinsic
GTP
GDP exchange rate but maintain normal GTP hydrolytic activity.
Thus, in vivo, these mutated ("fast-cycling") GTP-binding proteins become activated spontaneously, and more closely
reflect their in vivo activation by the Dbl oncoprotein. Indeed, we have previously shown that Cdc42(F28L) is activated in
vivo, and that its stable overexpression in NIH3T3 cells is accompanied by a few hallmarks of malignant transformation (18). Here,
we use the fast-cycling versions of Cdc42, Rac1, and RhoA (i.e. the primary GTP-binding protein targets of Dbl) to
assess their relative contributions to the total phenotype exhibited by
Dbl-transformed cells.
 |
EXPERIMENTAL PROCEDURES |
Molecular Constructs--
Rac1(F28L) and RhoA(F30L) mutations
were made using a polymerase chain reaction strategy identical to that
used earlier for generating the Cdc42(F28L) mutant (18). The reaction
included two internal primers harboring the Phe
Leu mutation, two
external pET15b primers, and a template of the wild-type gene in pET15b.
Expression of recombinant proteins in Escherichia coli was
performed exactly as described previously (18, 19). For transient expression in COS cells, the cDNAs encoding the GTP-binding
proteins were subcloned into the (HA-tagged) pKH3 vector or the
(Myc-tagged) pCDNA3 vector, using the
BamHI-EcoRI restriction sites. For stable expression in NIH3T3 cells, constructs were subcloned into the (HA-tagged) pJ4H vector using the same restriction sites. For focus
formation assays, a 3' BamHI site was added to all
constructs by polymerase chain reaction, and the
BamHI-BamHI fragments were subcloned into the
BamHI-digested pZipNeo vector, where correct orientation was
verified by restriction digestion.
Cell Culture--
Stable cell lines were generated by
co-transfection of NIH3T3 cells with the indicated genes in the pJ4H
vector, together with pCDNA3-Neo using the LipofectAMINE method
(Life Technologies, Inc.). Neomycin-resistant colonies were selected by
two consecutive culturing steps in DMEM supplemented with 10% calf
serum and neomycin (G418; 600 µg/ml; Life Technologies, Inc.).
Resistant colonies were screened for expression of the desired protein
by Western blotting the total lysates with anti-HA antibodies (HA.11;
Berkely Antibody Co.). The Dbl-expressing cell line was generated by
transformation of NIH3T3 cells with pZip-onco-Dbl (8), followed by the
isolation of a prominent focus and neomycin selection as described above.
For primary focus formation assays, the indicated constructs in the
pZipNeo vector were used to transfect subconfluent NIH3T3 cells in
6-well plates using the LipofectAMINE method. After 2 days, each well
was split into two 100-mm plates and cultured in DMEM supplemented with
10% calf serum. Two weeks after transfection, cells were fixed with
formaldehyde and stained with crystal violet, and foci were scored
under a microscope. For secondary focus formation assays, 1000 cells
stably expressing the indicated constructs were mixed with 2 × 105 NIH3T3 cells and cultured in DMEM supplemented with
10% calf serum. After 10 days, foci larger then 3 mm were scored from
fixed and stained plates.
Transfection protocols, cell culture and lysis, immunoprecipitation,
kinase assays, and soft-agar growth assays were described in detail
earlier (18, 20, 21).
Biochemical Assays--
Nucleotide exchange was monitored using
the mant-GDP fluorescence assay (22) or the binding of
[35S]GTP
S as described (23). For measurements of GTP
hydrolysis, 1 µM purified protein was incubated with 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM dithiothreitol, 0.5 mg/ml bovine serum albumin, 1 µM GTP, 100 nM [
-32P]GTP (30 Ci/mmol, NEN Life Science Products) in the presence of 15 mM EDTA for wild-type protein or 5 mM EDTA for
fast-cycling proteins, at room temperature for 20 min. Hydrolysis was
initiated by dilution with 20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM dithiothreitol, 0.5 mg/ml bovine
serum albumin, 20 mM MgCl2, with or without
0.01 µM Cdc42-GAP purified as described previously (23).
GTP hydrolysis was measured at room temperature for Cdc42 and Rac1 and
at 37 °C for RhoA.
PBD Assay--
This assay has been described in detail (24, 25).
Briefly, COS-7 cells were transiently transfected with the cDNA for the indicated GTP-binding protein in the pKH3 vector, with
or without oncogenic Dbl in the pCMV vector. Twenty-four hours
posttransfection, cells from 60-mm plates were lysed in 20 mM HEPES, pH 7.4, 150 mM NaCl, 1% Nonidet
P-40, 20 mM NaF, 20 mM
-glycerol-phosphate, 20 µM GTP, 1 mM sodium vanadate, and 10 µg/ml each of leupeptin and aprotonin and incubated with 50 µg of
recombinant glutathione S-transferase (GST)-PBD (20).
GST-PBD was then precipitated with glutathione-agarose beads, washed
three times with lysis buffer, and subjected to SDS-polyacrylamide gel
electrophoresis and immunoblotting using the indicated antibodies.
Fluorescence Microscopy--
Stable cell lines were cultured on
dual-chamber microscope slides (Nunc) for 2 days in normal media, and
then serum-starved for 12 h and fixed with 3.7% formaldehyde.
Slides were then sequentially incubated with anti-vinculin antibodies
(Sigma), Oregon Green-conjugated goat anti-mouse antibodies, Texas Red
phalloidin, and Hoechst-33342 (all from Molecular Probes). The slides
were visualized and photographed on a Nikon Eclipse 600 fluorescence microscope.
Tumorigenicity Assays--
The various stable cell lines were
cultured in DMEM supplemented with 10% calf serum, trypsinized, and
washed once with growth media and once with phosphate-buffered saline.
107 cells were injected subcutaneously into two dorsal
sites of athymic nude mice (CD-1; Charles River Laboratories). Visible
tumors (>0.5 cm) formed in the injection sites after the indicated
latency and grew progressively for another week.
 |
RESULTS |
Biochemical Characterization of the Fast-cycling Mutants of Cdc42,
Rac1, and RhoA
A phenylalanine residue corresponding to position 28 in Ras is
highly conserved in the Ras superfamily of small GTPases, in which it
has been shown to interact with the guanine base of the nucleotide
(26-29). Conservative substitution of this residue to a leucine
resulted in a reduced affinity of the protein to guanine nucleotides in
Ras (30) and Cdc42 (18), leading to spontaneous activation
(i.e. GTP binding) of the mutated protein when expressed in
cultured cells. We have generated the corresponding mutations in Rac1
and RhoA (i.e. Rac1(F28L) and RhoA(F30L)) and expressed and
purified these mutants to homogeneity from E. coli. The
ability of these purified proteins to bind GTP
S was compared, and is shown in Fig. 1A. As is
typical for all GTP-binding proteins, the wild-type versions of Rac1,
Cdc42, and RhoA show only negligible levels (<10%) of
[35S]GTP
S binding activity in the presence of 15 mM MgCl2. The addition of EDTA, which chelates
the tightly bound Mg2+ ion (31), leads to complete exchange
of the bound GDP for GTP
S (defined as 100% in Fig. 1A).
The Cdc42, Rac1, and RhoA point mutants, on the other hand, exhibit
significant [35S]GTP
S binding activity, even in the
presence of high Mg2+ (i.e. 63, 76, and 53% of
the maximal binding, respectively), indicating a significantly higher
basal nucleotide exchange activity. To fully assess the biochemical
properties of the mutated GTP-binding proteins, we have also measured
their ability to hydrolyze GTP in the presence and absence of the
Cdc42-GAP (32). The GTP-binding proteins were complexed with
[
-32P]GTP, and GTP hydrolysis was initiated by the
addition of Mg2+ (33). As can be seen from Fig.
1B, both the point-mutated Cdc42 and Rac proteins showed
intrinsic GTP hydrolytic rates that were comparable to their wild-type
counterparts. The intrinsic GTP hydrolytic activity of RhoA has been
consistently observed to be slower than the corresponding activities
for Rac and Cdc42, and this activity is slightly reduced (by 30-50%)
in the fast-cycling RhoA mutant. A similar affect has been seen when
examining the analogous point mutation in Ras (30). More importantly,
each of the point mutants is fully responsive to GAP stimulation,
yielding turnover numbers for GTP hydrolysis that are virtually
indistinguishable from those for the wild-type proteins. Taken
together, our in vitro results indicate that Cdc42(F28L),
Rac1(F28L), and RhoA(F30L) all exhibit significantly higher GTP
GDP
exchange activity compared with their wild-type counterparts but
maintain GTP hydrolytic capability. Because of their inherent ability
to rapidly undergo GDP-GTP exchange and still hydrolyze GTP (thereby
undergoing a fast GTP-binding/GTPase cycle), we have referred to these
point mutants as fast-cycling mutants. It was our expectation that
these mutants would be constitutively active in vivo
(i.e. without the involvement of an extracellular signal or
GEF activity), due to the high GTP:GDP ratio in cytosol (34).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 1.
Cdc42(F28L), Rac1(F28L), and RhoA(F30L) are
fast-cycling in vitro. A,
[35S]GTP S binding. One µM purified
wild-type or mutated proteins were incubated with 10 µM
[35S]GTP S (0.3 Ci/mmol) in the absence (empty
bars) or presence (hatched bars) of 20 mM
EDTA, and protein-bound radioactivity was measured using nitrocellulose
filtration. B, GTP hydrolysis. One µM
wild-type or mutant proteins were incubated with 0.1 µM
[ -32P]GTP (30 Ci/mmol) in the absence (empty
bars) or presence (hatched bars) of 0.01 µM Cdc42-GAP. Aliquots were removed after 2, 5, 10, 20, and 30 min, and protein-bound radioactivity was measured by
nitrocellulose filtration. The half-life for GTP hydrolysis was
obtained by fitting the data to a single exponential process. Data
shown are the means of two duplicate measurements (S.E., <10%). *,
RhoA GTPase assays were carried out at 37 °C.
|
|
Cdc42(F28L), Rac1(F28L), and RhoA(F30L) Are Activated in
Vivo
Biochemical Evidence--
In vivo activation of Cdc42,
Rac, and Rho is accompanied by diverse biological phenotypes
accomplished through interactions with different target proteins. To
assess whether the Phe
Leu mutation indeed results in the
spontaneous activation of the different GTP-binding proteins in
vivo, we have utilized a modification of an assay developed to
assess the activation level of Ras (24, 25). This assay is based on the
GTP-specific high affinity interaction between the tested GTP-binding
protein and the binding domain of its target, PAK-3 (20), which is
fused to GST to enable affinity precipitation. Thus, a recombinant GST
fusion protein containing the p21-binding domain (PBD, also known as
the CRIB (Cdc42/Rac-interaction binding) domain) (35) of PAK-3
immobilized on glutathione-agarose was incubated with lysates from
COS-7 cells transfected with the different forms of Cdc42 and Rac1.
Following extensive washes, the lysates (Fig.
2A, middle panel) and the
precipitated GST-PBD beads (Fig. 2A, top panel) were
electrophoresed and blotted for the (HA-tagged) GTP-binding proteins.
Fig. 2A, middle panel, shows that each of the GTP-binding
proteins were expressed to significant and similar levels. As expected,
the co-expression of Cdc42 and Dbl (compare lanes 1 and
5), as well as Rac1 and Dbl (compare lanes 3 and
6), resulted in the enhanced precipitation of the GTP-binding protein, indicating that Dbl activates each of these proteins in cells. More importantly, the amounts of the fast-cycling versions of Rac1 and Cdc42 precipitated with GST-PBD were markedly higher than those of the wild-type GTP-binding proteins (compare lanes 1 and 2 or lanes 3 and
4). We have used this assay also to compare the activation
level of the fast-cycling version (F28L) with that of the
GTPase-defective version (Q61L) of Cdc42 and Rac1. Under essentially
identical experimental conditions, 20% of the expressed Cdc42(Q61L)
precipitated with GST-PBD, versus 18% of the fast-cycling,
Cdc42(F28L) mutant (± 2%; data not shown). This verifies that a
significantly larger fraction of each Phe
Leu mutant is in the
GTP-bound state, compared with the corresponding wild-type protein, and
is consistent with the idea that the fast-cycling versions of Cdc42 and
Rac1 are spontaneously activated when ectopically expressed in cultured
cells.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 2.
Fast-cycling mutants of Cdc42, Rac1, and RhoA
are activated in vivo. A, PBD precipitation
assay. COS-7 cells were transiently transfected with the indicated
HA-tagged variants of Cdc42 and Rac1 in the pKH3 vector with or without
the onco-Dbl gene in the pCMV vector. After 24 h, cell lysates
were incubated with purified, bacterially expressed GST-PBD for 2 h, and precipitated with glutathione-agarose. Precipitates were washed
extensively, subjected to SDS-polyacrylamide gel electrophoresis, and
immunoblotted using anti-HA antibodies to visualize GTPases that
co-precipitate with the GST-PBD (top panel). Additionally,
total lysates were blotted with anti-HA and anti-vinculin antibodies to
assess the relative expression of the GTP-binding proteins
(middle panel) and to ensure equal protein loading on the
gel (bottom panel), respectively. NIH Image Version 1.61 software was used to quantitate the fraction of the GTP-binding protein
that was precipitated relative to the total expressed protein in each
experiment. B, JNK activation. COS-7 cells were transiently
transfected with the indicated variants of Rac1 in the pCDNA3
vector and with pCDNA3-Flag-JNK. JNK was immunoprecipitated from
lysates using the M5 antibody (BabCo. Inc.), and kinase activity was
assayed in vitro using recombinant GST-c-Jun as a substrate.
C, JNK activity in stable cell lines. NIH3T3 lines stably
expressing fast-cycling Cdc42, Rac1, RhoA, and onco-Dbl were selected
as described under "Experimental Procedures." Lysates prepared from
confluent 100-mm plates were immunoblotted with anti-HA antibody to
assess the relative expression levels of the GTP-binding proteins
(bottom panel). Recombinant c-Jun was used to isolate and
assay endogenous JNK1 activity (top panel) as described
(18).
|
|
Another well characterized signaling end point for Cdc42 and Rac1 is a
nuclear transcriptional activator, the c-Jun kinase (JNK1) (21, 36,
37). We have previously reported that the expression of the Cdc42(F28L)
mutant in COS-7 cells leads to activation of JNK1 (18). We show here
that this is also true for the Rac1(F28L) mutant. Fig. 2B
shows the results of an experiment in which wild-type Rac1, the
GTPase-defective Rac1(Q61L) mutant, and the fast-cycling Rac1(F28L)
mutant were co-transfected into COS-7 cells together with flag-tagged
JNK1, and then immunocomplex kinase assays were performed following
anti-flag immunoprecipitation. The JNK1 precipitated from cells
expressing the Rac1(F28L) mutant exhibited levels of protein kinase
activity (measured by the phosphorylation of c-Jun) that were
comparable to those measured in cells expressing the Rac1(Q61L) mutant
and significantly higher than the activity precipitated from cells
expressing wild-type Rac1 or vector alone.
We have also established NIH3T3 cell lines that stably express
HA-tagged forms of Cdc42(F28L), Rac1(F28L), and RhoA(F30L). Taking
advantage of the high affinity interaction between JNK and c-Jun, we
examined the endogenous JNK activity in these stable cell lines as well
as from cells expressing the oncogenic Dbl protein. Lysates from the
different cell lines were incubated with recombinant GST-c-Jun
immobilized on glutathione beads. The precipitated GST-Jun·JNK1
complexes were washed, incubated with MgCl2 and
[
-32P]ATP, electrophoresed, and autoradiographed. JNK
activity, visualized as 32P incorporation into the GST-Jun
protein, is shown in Fig. 2C. It is clear from these data
that JNK activity is stimulated 3-5-fold in cell lines expressing
fast-cycling Cdc42, Rac1, or oncogenic Dbl, relative to
mock-transfected cells. Stimulation of JNK activity by fast-cycling
RhoA, can be detected only in cells expressing relatively high levels
of RhoA(F30L), in accordance with previous reports (36, 37).
Cytoskeletal Evidence--
Another well established end point for
the activation of Cdc42, Rac, and Rho is cytoskeletal reorganization
(38). The controlled dynamic rearrangements of actin-based cytoskeletal
elements have been shown to play important roles in motility (39-43),
differentiation (44-46), the establishment of cell polarity (47, 48),
and growth factor-induced cell shape changes (49-51). We have
therefore undertaken a systematic investigation of the cytoskeletal
changes associated with the stable overexpression of Cdc42(F28L),
Rac1(F28L), or RhoA(F30L) in the cell lines described above. Standard
optical microscopy revealed that each cell line displayed distinct
morphological characteristics that were especially evident in low
density (<30% confluence) cultures (Fig.
3). Cells stably expressing Cdc42(F28L) were elongated with multiple extensions (Fig. 3,
Cdc42(F28L), right panel). Cells that expressed
RhoA(F30L) exhibited pronounced extensions, similar to those observed
in Lbc-transformed cells (52), whereas cells that expressed Rac1(F28L)
lacked any visible extensions from the cell surface but exhibited
thickened cell borders, possibly reflecting lamellipodia (Fig. 3,
RhoA(F30L) and Rac1(F28L), right panels). These
morphological phenotypes are in agreement with those observed upon
microinjection of the GTPase-defective versions of these GTP-binding
proteins into Swiss-3T3 fibroblasts, (53). In addition, we found that
approximately 3% of the Cdc42(F28L)-expressing cells exhibit a giant
cell, multinucleate morphology, similar to Dbl-transformed fibroblasts
(Fig. 3, Cdc42(F28L), left panel; see also Refs. 18 and
1).

View larger version (113K):
[in this window]
[in a new window]
|
Fig. 3.
Morphological characteristics of
Cdc42(F28L)-, Rac1(F28L)-, and RhoA(F30L)-expressing fibroblasts.
NIH3T3 fibroblasts stably transfected with the indicated constructs
were isolated as described under "Experimental Procedures." Cells
were cultured to confluence (left panels) (magnification, × 100) or subconfluence (right panels) (magnification, × 200)
in tissue culture dishes and visualized by light microscopy.
White arrows point to cells with giant, multinucleate
phenotype in the left panels and to cortical cytoskeletal
structures (lamellipodia) in the right panels.
|
|
We further investigated these morphological phenotypes using specific
optical staining coupled to fluorescence microscopy as shown in Fig.
4. The various NIH3T3 stable cell lines
were cultured on chamber slides, serum-starved for 24 h, fixed,
and specifically stained for F-actin (using Texas Red-conjugated
phalloidin) (Fig. 4, middle panels), for focal complexes
(using monoclonal anti-vinculin antibodies and Oregon Green-conjugated
anti-mouse IgG) (Fig. 4, bottom panels), and for nuclei
(using Hoechst-33342 dye).

View larger version (81K):
[in this window]
[in a new window]
|
Fig. 4.
Cytoskeletal rearrangements in cell lines
stably expressing fast-cycling GTPases and onco-Dbl. The indicated
stable cell lines were cultured on microscope chambers and fixed with
3.7% formaldehyde. Filamentous actin structures were visualized using
Texas Red-conjugated Phalloidin, focal adhesion complexes were
visualized with anti-vinculin antibodies followed by Oregon
Green-conjugated anti-mouse IgG (Molecular Probes), and Hoechest 33342 stain was used for nuclear staining. Treated slides were observed under
a Nikon Eclipse 600 fluorescence microscope (magnification, × 400).
The top panels (triple) show the combined
fluorescence from all three stains, obtained by a multichromatic
filter. Control cells (left panels) represent NIH3T3 cells
mock-transfected with empty vector and selected for antibiotic
resistance as the other cell lines. Bottom two panels show
actin staining pattern of mononucleated Dbl and Cdc42(F28L) cells
(magnification, × 600).
|
|
Control NIH3T3 cells (i.e. transfected with empty vector and
selected for antibiotic resistance like the other cell lines) showed
the typical extended cell shape with a single nucleus, well oriented
stress fibers, and a relatively small number of focal adhesion
complexes. Dbl-transformed cells showed an enhanced actin staining
(although the stress fibers appeared disorganized), with a significant
fraction (8-12%) of the cells being large and multinucleated. The
cells expressing oncogenic Dbl also exhibited cortical actin structures
along the cell periphery, with a pronounced "crown-like" array of
vinculin-containing focal adhesion complexes along the cell border.
Cell lines expressing the fast-cycling mutants displayed very
characteristic morphological changes that confirmed and extended the
phenotypes observed by regular microscopy described above. A fraction
of the cells expressing the Cdc42(F28L) mutant are giant and
multinucleate, similar to the phenotype observed for cells expressing
oncogenic Dbl. However, the F-actin staining pattern was very unique to
the Cdc42(F28L)-expressing cells, as characterized by a vast array of
actin microspikes extending outward from the cell surface, each of
which has a single focal adhesion complex at its tip.
RhoA(F30L)-expressing fibroblasts displayed a dramatic increase in the
number of well oriented stress fibers, accompanied by numerous,
enlarged focal adhesion complexes. Neither the Cdc42(F28L)- nor
RhoA(F30L)-expressing cells showed significant cortical actin
structures. This was markedly different from the Rac1(F28L)-expressing
cells, which exhibited significantly fewer stress fibers (those
detected were relatively short and disorganized) but displayed a
prominent arrangement of cortical actin at the leading edge of the cell (lamellipodia).
A few conclusions can be drawn from the comparative morphologies of the
different cell lines. First, when stably expressed in fibroblasts, the
fast-cycling mutants of Cdc42, Rac1, and RhoA give rise to unique
morphological characteristics (the formation of filopodia,
lamellipodia, and actin stress fibers, respectively), lending
additional support to the notion that these mutants are spontaneously
activated in vivo. Secondly, the morphological
characteristics of Dbl-transformed cells possess features that can be
observed in each of the individual fast-cycling cell lines,
i.e. some of the cells are large and multinucleated, and all
cells exhibit enhanced stress fibers, cortical actin, and focal
adhesion complexes. We interpret this to indicate that in
Dbl-transformed cells, all three GTP-binding proteins are activated,
with each protein contributing a unique characteristic to the overall
morphology of Dbl-expressing cells.
Rho GTP-binding Proteins Mediate Cellular Transformation
The availability of stable cell lines that express high levels of
the fast-cycling mutants of Rac, Rho, and Cdc42 provides us with
valuable tools to directly investigate the effects of these
spontaneously activated GTP-binding proteins on various parameters of
cell growth. We have first compared the saturation density and growth
rate of the different cell lines in both normal and low serum
conditions (5 and 0.5% calf serum, respectively), as shown in Fig.
5. A few clear differences were observed
upon examining these data. Clearly, cell lines stably expressing high levels of the fast-cycling GTP-binding proteins reached saturation densities that were 3-5-fold higher than those reached by control cells (Fig. 5A). Dbl-transformed cells actually grew to a
lower density under these conditions (5% serum) compared with cell
lines that expressed the fast-cycling mutants. This most likely is due to a particularly large fraction (approximately 10%) of the
Dbl-expressing cells being blocked in cytokinesis. At the present time,
we do not know why the Dbl-transformed cells show such a striking
giant-cell phenotype under conditions of high serum (even compared with
Cdc42(F28L)-expressing cells). Apparently, Dbl-mediated activation
causes a large percentage of the fibroblasts to uncouple an accelerated
cell cycle progression and nuclear division from cytokinesis. Under low
serum conditions (0.5% calf serum) (Fig. 5B), the growth of
control cells was arrested during the first 24 h, followed by a
progressive cell death. Cell lines expressing the fast-cycling
GTP-binding proteins and Dbl-transformed cells, on the other hand, were
able to steadily proliferate in low serum conditions (Fig.
5B).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of fast-cycling GTPases results in
increased saturation density and diminished serum dependence.
A, cell lines stably expressing the indicated constructs
were cultured in DMEM supplemented with 5% calf serum for 7 days,
trypsinized, and counted. Data are average of three duplicate plates.
B, indicated cell lines were cultured in DMEM supplemented
with 0.5% calf serum. At the indicated times, cells from 35-mm plates
were trypsinized and counted. Data shown are the averages from
duplicate plates.
|
|
Overall, the data presented in Fig. 5 show that activation of Cdc42,
Rac1, and RhoA is accompanied by two hallmarks of cellular transformation: loss of contact inhibition and diminished serum dependence. An additional parameter that distinguishes normal from
transformed cells is the requirement for attachment to an extracellular
substratum (i.e. anchorage dependence (54)). As indicated in
Table I, constitutive expression of
Cdc42(F28L) caused pronounced growth in soft agar and typically
exceeded the soft agar colony formation associated with Dbl expression
(see also Ref. 18). Expression of the fast-cycling Rac1 and RhoA mutants, on the other hand, was accompanied by only a weak colony formation. Thus, it appears that anchorage-independent growth exhibited
by Dbl-transformed cells is mediated mainly through the activation of
Cdc42.
View this table:
[in this window]
[in a new window]
|
Table I
Anchorage-independent growth and tumorigenicity by cell lines stably
expressing fast-cycling GTP-binding proteins and onco-Dbl
|
|
Focus formation is widely used for assaying the loss of contact
inhibition by transformed cells (55, 56) and, in fact, led to the
original identification of Dbl from diffuse B-cell lymphoma DNA (1). We
have utilized the stably transfected cell lines described above in a
"secondary" focus formation assay (17), in which each of the cell
lines was mixed with parental NIH3T3 cells at a ratio of 1:200 and
plated under normal conditions (2 × 105 cells/100-mm
plate, 5% calf serum). After 10 days, the cells were fixed and
stained, and foci larger then 2 mm were scored under the microscope. As
shown in Fig. 6A, only a small
number of foci were consistently observed in cells expressing the
fast-cycling mutants of Rac and Cdc42. However, cells expressing the
RhoA(F30L) mutant showed focus forming capability that was dependent on
the levels of Rho(F30L) expression (Fig. 6, B and
C), reaching 80% of the number of foci formed by
Dbl-transformed cells.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Focus formation by activated GTPases.
A, 103 NIH3T3 cells stably expressing the
indicated proteins were mixed with 2 × 105 of
parental NIH3T3 cells and cultured in 100-mm plates in the presence of
10% calf serum. After 10 days, cells were fixed and stained with
crystal violet, and foci larger then 2 mm were counted. Data are
representative of three independent experiments. Error
bars represent the variation of duplicates in one experiment.
B, quantitation of the ability of different
RhoA(F30L)-expressing clones to generate secondary foci. Conditions
were as in A. C, expression of RhoA(F30L) in the
different clones as assessed by anti-HA immunoblotting.
|
|
We observed a similar differential potency exhibited by the different
GTP-binding proteins in primary focus formation assays. Specifically,
in experiments in which activated alleles of RhoA, Cdc42, or Rac1 (in
the pZipNeo vector) were transfected into NIH3T3 cells, only RhoA
transfections yielded a significant number of foci (data not shown).
However, we have not been able to observe any synergism upon the
co-transfection of the three fast-cycling mutants of Cdc42, Rac, and
Rho (i.e. the number of foci observed upon transfection of
activated RhoA did not change upon the addition of cDNAs encoding
for activated forms of Cdc42 and Rac1 to the transfection mixture in a
primary focus formation assay). We therefore conclude that the focus
forming activity associated with transformation by the dbl
oncogene is an outcome of its ability to specifically activate
RhoA and that the other, related GTP-binding proteins do not
participate significantly in promoting this specific biological activity.
It is interesting that each of these GTP-binding proteins exhibits
tumorigenic activity (Table I). The subcutaneous injection of cell
lines that individually express each of the fast-cycling GTP-binding
proteins into immunocompromised (athymic) nude mice resulted in
significant (>10 mm) formation of solid tumors after 2 weeks. Although
no significant differences were observed between the different
fast-cycling cell lines with regards to tumorigenic potency and
latency, cells overexpressing oncogenic Dbl exhibited a significantly
shorter latency period (Table I).
It appears that each GTP-binding protein mediates a different aspect of
the transformed phenotype induced by Dbl. RhoA activation is the main
contributor to the loss of contact inhibition (focus formation) and to
the increase in stress fiber content and the number of focal adhesion
complexes, Rac1 activation accounts for the accumulation of cortical
actin at the cell periphery observed in Dbl-transformed cells, and the
activation of Cdc42 provides for anchorage independence and filopodia
formation and leads to the generation of large, multinucleated cells.
 |
DISCUSSION |
The Dbl-related proteins represent an interesting and growing
family of oncogene products and cell growth regulatory factors. Members
of the family were originally isolated as the transforming genes from
lymphomas (1, 57, 58), osteosarcomas (59), leukemias (60, 61), and
other malignancies (62), and all contain a tandem arrangement of a
pleckstrin homology domain and a Dbl homology domain (for review, see
Ref. 3). In the case of the prototypical member of the family, the Dbl
oncoprotein, the Dbl homology/pleckstrin homology domain tandem
represents the minimal unit for transformation activity (8). Thus far, the only biochemical activity that has been assigned to Dbl and other
members of the family is the stimulation of the guanine nucleotide
exchange activity of Rho-related GTP-binding proteins, such as Cdc42,
Rac, and Rho (3). This has led to the common assumption that any
protein that contains the Dbl homology/pleckstrin homology domain
tandem is a GEF for a Rho-related GTP-binding protein. Similarly, it
has been generally assumed that the high transformation capability
exhibited by many members of the Dbl family, including Dbl itself, is
the direct outcome of their GEF activity (i.e. through the
activation of a Rho-related protein and its downstream signaling pathway).
A number of attempts have been made to elucidate the mechanism of Dbl
transformation by overexpression of mutated Cdc42, Rac, and Rho
proteins in various cell culture models. A role for Rho proteins in
Ras-induced transformation has been established from studies
demonstrating that dominant-negative Rho proteins block Ras
transformation and from the observation of synergistic co-operativity between activated Raf and GTPase-defective versions of either RhoA,
Rac1, or Cdc42 (12-15). Furthermore, cell lines expressing these
GTPase-defective Rho proteins were shown to be tumorigenic and
exhibited some aspects of cellular transformation in tissue culture
assays (11-15, 63-65). However, these studies did not conclusively resolve the basis of Dbl-induced transformation for two reasons. First,
although Dbl is potently transforming, its GTP-binding protein targets
have only weak transforming activity when individually expressed in
cultured fibroblasts. Second, no unified conclusion can be reached
based on the different reports with regards to the proliferative
outcome of a particular activated GTP-binding protein. For example,
fibroblasts overexpressing GTPase-defective versions of RhoA
(RhoA(Q63L) or RhoA(G14V)) were shown by some researchers (11, 15) to
grow to high saturation densities, exhibit diminished serum dependence,
and induce solid tumors in nude mice, whereas in other reports (13, 65,
66), they showed none of these transformation hallmarks. One possible
explanation for such discrepancies is the varying levels of expression
of the Rho proteins in the different cell lines studied. However, another possible explanation is that the GTPase-defective mutants of
Rho-related proteins do not exactly reflect the GEF-mediated activation
state of small G proteins. In support of this notion is our experience
that constitutive expression of the Cdc42(Q61L) mutant can actually
have detrimental effects on cell growth (18). Thus, in the current
study, we have examined this issue in detail, with a particular
emphasis on utilizing physiologically relevant activation mutants and
understanding the roles of the different GTP-binding proteins in the
complete transformation phenotype induced by Dbl.
Because of the difficulties that we have previously encountered in
generating stable NIH3T3 cell lines that express GTPase-defective Cdc42, we set out to identify a mutation within the Cdc42, Rac, and
RhoA proteins that would more closely mimic the functional effects of
oncogenic Dbl. Specifically, we looked for a mutation that would allow
these Dbl targets to be constitutively active through the spontaneous
binding of GTP without altering their ability to cycle between the GTP-
and GDP-bound states via GTP hydrolysis. We first found that a
Cdc42(F28L) point mutant showed such properties (18), and in the
present study, we have used this fast-cycling mutant together with the
corresponding point mutants for Rac1 and RhoA to examine the
contributions of these G proteins to the Dbl-transformed phenotype. As
expected, the fast-cycling mutants of Cdc42, Rac1, and RhoA behave as
activated G proteins in cells. The Cdc42(F28L) mutant gives rise to
filopodia formation and, like Rac(F28L), stimulates JNK activity,
whereas the RhoA(F30L) mutant induces actin stress fibers and the
formation of focal complexes.
A number of interesting and surprising points have emerged when
directly comparing the activities of each of the fast-cycling mutants
versus oncogenic Dbl in different cell transformation assays. Perhaps foremost has been the realization that each of these
Dbl targets are capable of contributing to distinct aspects of the total transformation induced by Dbl. For example, expression of
Cdc42(F28L) promotes growth in soft agar with essentially identical capability as oncogenic Dbl, whereas neither the fast-cycling Rac1 nor
RhoA mutants show comparable colony formation in semisolid media (Table
I). Like Dbl, Cdc42(F28L) also appears to uncouple cell cycle
progression and nuclear division from cell division, such that a
detectable fraction (3-5%) of Cdc42(F28L)-expressing NIH3T3 cells are
giant and multinucleate. On the other hand, only the fast-cycling RhoA
mutant appears to induce significant focus formation activity, whereas
both the Cdc42(F28L) mutant and the Rac(F28L) mutant are ineffective in
these assays (Fig. 6). As a matter of fact, the focus forming activity
measured in cells that express high levels of RhoA(F30L) approaches
that measured in Dbl-transformed cells. Apparently, the ability of the
RhoA(F30L) mutant to continuously cycle between the GDP and GTP states
enables high level expression of the activated protein and,
consequently, potent focus forming activity. This may explain why
significant focus formation has not been detected in experiments in
which the GTPase-defective RhoA mutants were used (13, 65, 66).
The observation that each GTP-binding protein mediates a distinct facet
of cell transformation immediately raises the issue of identity of the
specific downstream target(s) that mediates the particular signal. In
this regard, inhibition of Dbl-induced focus formation was observed in
the presence of a specific inhibitor of the RhoA target, p160-ROCK
(66), suggesting that this effector kinase mediates the focus formation
activity initiated by RhoA. Activation of Rac in neutrophils (67, 68),
REF-52 cells, and COS cells (69) was shown to result in potent
activation of NADPH oxidase, leading to a robust increase in
intra-cellular levels of reactive oxygen species (O
2).
Importantly, Rac-mediated elevation in O
2 levels was shown to
be a critical component of cell cycle progression (69) and Ras-induced
transformation (70) in NIH3T3 cells. The Cdc42 effector, which mediates
anchorage-independent growth, is more enigmatic; thus far, none of the
known targets for this GTP-binding protein have been shown to
potentiate such a phenotype. The availability of the fast-cycling Cdc42
should facilitate the identification of this target/effector.
It is interesting that NIH3T3 cells that express any of the three
fast-cycling mutants, Cdc42(F28L), Rac(F28L), and RhoA(F30L), are able
to grow to high density (i.e. lose normal contact
inhibition) and to grow in low serum. For the case of Cdc42, these
results differ from those reported by other groups (14, 63) when using a GTPase-defective Cdc42 mutant. We suspect that the inability of cells
expressing the GTPase-defective Cdc42 to grow to high densities, or to
grow in reduced serum levels, most likely reflects the difficulties
that we faced when trying to generate stable cell lines overexpressing
GTPase-defective Cdc42, and it argues for the advantage in studying
a fast-cycling Cdc42 mutant when trying to assess the contributions
that Cdc42 makes to Dbl-induced transformation. Apparently, it is the
ability of the fast-cycling Rac mutant to allow cells to grow to high
density and in low serum that explains how cells expressing this mutant
generate tumors in nude mice.
Thus, all three of the Dbl targets, when constitutively active but
still GTPase-competent, can alter different aspects of the regulation
of normal cell growth and thereby initiate tumorigenic signals. The
ability of Dbl to give rise to a potent malignant transformation signal
apparently reflects its ability to activate each of these small G
protein signaling pathways (depicted schematically in Fig.
7). This would suggest that oncogene
products need not necessarily be capable of exhibiting all
characteristics associated with cellular transformation, although those
that do will have the greatest likelihood to elicit a potent
tumorigenic outcome. Although it was tempting to speculate that
activated Cdc42, Rac, and RhoA would act synergistically to fully
reproduce the actions of oncogenic Dbl, as might be inferred from the
results of other studies (63), we have not been able to directly
demonstrate such cooperation between these Dbl targets when assaying
different aspects of cellular transformation. This may in part reflect
the formidable problem of generating cell lines that have adequate expression of all three (fast-cycling) GTP-binding proteins and the
likelihood that there exists a carefully coordinated timing in the
Dbl-stimulated activation of each of these GTP-binding proteins that
cannot be reproduced through their simple co-expression in cells.
However, the development of fast-cycling mutants and cell lines that
express each of the Dbl substrates now offers an exciting opportunity
to dissect the different aspects of the total transforming signal
induced by a potent oncoprotein. In the future, these tools should
yield new insights into the molecular mechanisms that underlie each of
the individual cellular activities that contribute to the total
malignant phenotype.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 7.
Schematic depiction of the basis for
Dbl-induced transformation via activation of the GTP-binding proteins
RhoA, Rac1, and Cdc42.
|
|
 |
ACKNOWLEDGEMENTS |
We are grateful to Larry Carbone for expert
help in assessing the tumorigenic effects in nude mice and to Cindy
Westmiller for expert secretarial assistance.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant GM47458 (to R. A. C.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Div. of
Nutritional Sciences, Savage Hall, Rm. 312, Cornell University, Ithaca, NY 14853. Tel.: 607-255-6085; Fax: 607-255-1033; E-mail:
dm43@cornell.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
GEF, guanine
nucleotide exchange factor;
HA, hemagglutinin;
JNK, c-Jun
NH2-terminal kinase;
DMEM, Dulbecco's modified Eagle's
medium;
GAP, GTPase activating protein;
GST, glutathione
S-transferase;
GTP
S, guanosine
5'-3-O-(thio)triphosphate.
 |
REFERENCES |
| 1.
|
Eva, A.,
and Aaronson, S. A.
(1985)
Nature
316,
273-275[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Ron, D.,
Tronick, S. R.,
Aaronson, S. A.,
and Eva, A.
(1988)
EMBO J.
7,
2465-2473[Medline]
[Order article via Infotrieve]
|
| 3.
|
Cerione, R. A.,
and Zheng, Y.
(1996)
Curr. Opin. Cell Biol.
8,
205-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Whitehead, I. P.,
Campbell, S.,
Rossman, K. L.,
and Der, C. J.
(1997)
Biochim. Biophys. Acta
1332,
F1-F23[Medline]
[Order article via Infotrieve]
|
| 5.
|
Boguski, M. S.,
and McCormick, F.
(1993)
Nature
366,
643-654[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Bourne, H. R.,
Sanders, D. A.,
and McCormick, F.
(1990)
Nature
348,
125-131[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Hall, A.
(1990)
Science
249,
635-640[Abstract/Free Full Text]
|
| 8.
|
Hart, M. J.,
Eva, A.,
Zangrilli, D.,
Aaronson, S. A.,
Evans, T.,
Cerione, R. A.,
and Zheng, Y.
(1994)
J. Biol. Chem.
269,
62-65[Abstract/Free Full Text]
|
| 9.
|
Sigal, I. S.,
Gibbs, J. B.,
D'Alonzo, J. S.,
Temeeles, G. L.,
Wolanski, B. S.,
Socher, S. S.,
and Scolnick, E. M.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
952-956[Abstract/Free Full Text]
|
| 10.
|
Barbacid, M.
(1987)
Annu. Rev. Biochem.
56,
779-827[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Avraham, H.,
and Weinberg, R.
(1989)
Mol. Cell. Biol.
9,
2058-2066[Abstract/Free Full Text]
|
| 12.
|
Qiu, R. G.,
Chen, J.,
Kirn, D.,
McCormick, F.,
and Symons, M.
(1995)
Nature
374,
457-459[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Qiu, R. G.,
Chen, J.,
McCormick, F.,
and Symons, M.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11781-11785[Abstract/Free Full Text]
|
| 14.
|
Qiu, R. G.,
Abo, A.,
McCormick, F.,
and Symons, M.
(1997)
Mol. Cell. Biol.
17,
3449-3458[Abstract]
|
| 15.
|
Khosravi-Far, R.,
Solski, P. A.,
Clarck, G. J.,
Kinch, M. S.,
and Der, C. J.
(1995)
Mol. Cell. Biol.
15,
6443-6453[Abstract]
|
| 16.
|
Westwick, J. K.,
Lambert, Q. T.,
Clarck, G. J.,
Symons, M.,
Van Aelst, L.,
Pestell, R. G.,
and Der, C. J.
(1997)
Mol. Cell. Biol.
17,
1324-1335[Abstract]
|
| 17.
|
Whitehead, I. P.,
Abe, K.,
Gorski, J. L.,
and Der, C. J.
(1998)
Mol. Cell. Biol.
18,
4689-4697[Abstract/Free Full Text]
|
| 18.
|
Lin, R.,
Bagrodia, S.,
Cerione, R.,
and Manor, D.
(1997)
Curr. Biol.
7,
794-797[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Leonard, D. A.,
Sartoskar, R.,
Wu, J. W.,
Cerione, R. A.,
and Manor, D.
(1997)
Biochemistry
36,
1173-1180[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Bagrodia, S.,
Taylor, S.,
Creasy, C.,
Chernoff, J.,
and Cerione, R.
(1995)
J. Biol. Chem.
270,
22731-22737[Abstract/Free Full Text]
|
| 21.
|
Bagrodia, S.,
Derigard, B.,
Davis, R. J.,
and Cerione, R. A.
(1995)
J. Biol. Chem.
270,
27995-27998[Abstract/Free Full Text]
|
| 22.
|
Leonard, D. A.,
Evans, T.,
Hart, M.,
Cerione, R. A.,
and Manor, D.
(1994)
Biochemistry
33,
12323-12328[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Leonard, D. A.,
Lin, R.,
Cerione, R. A.,
and Manor, D.
(1998)
J. Biol. Chem.
273,
16210-16215[Abstract/Free Full Text]
|
| 24.
|
Taylor, S. J.,
and Shalloway, D.
(1996)
Curr. Biol.
6,
1621-1627[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Bagrodia, S.,
Taylor, S. J.,
Jordon, K. A.,
Van Aelst, L.,
and Cerione, R. A.
(1998)
J. Biol. Chem.
273,
23633-23636[Abstract/Free Full Text]
|
| 26.
|
Pai, E. F.,
Kabsch, W.,
Krengel, U.,
Holmes, K. C.,
John, J.,
and Wittinghofer, A.
(1989)
Nature
341,
209-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Feltham, J.,
Dotch, V.,
Raza, S.,
Manor, D.,
Cerione, R.,
Sutcliffe, M.,
Wagner, G.,
and Oswald, R.
(1997)
Biochemistry
36,
8755-8766[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Hirshberg, M.,
Stockley, R. W.,
Dodson, G.,
and Webb, M. R.
(1997)
Nature Struct. Biol.
4,
147-151[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Wei, Y.,
Zhang, Y.,
Derewenda, U.,
Liu, X.,
Minor, W.,
Nakamoto, R. K.,
Somlyo, A. V.,
Somlyo, A. P.,
and Derewenda, Z. S.
(1997)
Nat. Struct. Biol.
4,
699-703[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Reinstein, J.,
Schlichting, I.,
Frech, M.,
Goody, R.,
and Wittinghofer, A.
(1991)
J. Biol. Chem.
266,
17700-17706[Abstract/Free Full Text]
|
| 31.
|
Hall, A.,
and Self, A. J.
(1986)
J. Biol. Chem.
261,
10963-10965[Abstract/Free Full Text]
|
| 32.
|
Barfod, E. T.,
Zheng, Y.,
Kuang, W. J.,
Hart, M. J.,
Evans, T.,
Cerione, R. A.,
and Ashkenazi, A.
(1993)
J. Biol. Chem.
268,
26059-26062[Abstract/Free Full Text]
|
| 33.
|
Hart, M. J.,
Maru, Y.,
Leonard, D.,
Witte, O. N.,
Evans, T.,
and Cerione, R. A.
(1992)
Science
258,
812-815[Abstract/Free Full Text]
|
| 34.
|
Otero, A. D.
(1990)
Biochem. Pharmacol.
39,
1399-1404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Burbelo, P. D.,
Drechsel, D.,
and Hall, A.
(1995)
J. Biol. Chem.
270,
29071-29074[Abstract/Free Full Text]
|
| 36.
|
Minden, A.,
Lin, A.,
Claret, F. X.,
Abo, A.,
and Karin, M.
(1995)
Cell
81,
1147-1157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Coso, O. A.,
Chiariello, M., Yu, J. C.,
Teramoto, H.,
Crespo, P.,
Xu, N.,
Miki, T.,
and Gutkind, J. S.
(1995)
Cell
81,
1137-1146[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Hall, A.
(1998)
Science
279,
509-514[Abstract/Free Full Text]
|
| 39.
|
Keely, P. J.,
Westwick, J. K.,
Whitehead, I. P.,
Der, C. J.,
and Parise, L. V.
(1997)
Nature
390,
632-636[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Price, L. S.,
Leng, J.,
Schwartz, M. A.,
and Bokoch, G. M.
(1998)
Mol. Biol. Cell
9,
1863-1871[Abstract/Free Full Text]
|
| 41.
|
Allen, W. E.,
Zicha, D.,
Ridley, A. J.,
and Jones, G. E.
(1998)
J. Cell Biol.
141,
1147-1157[Abstract/Free Full Text]
|
| 42.
|
Santos, M. F.,
McCormack, S. A.,
Guo, Z.,
Okolicany, J.,
Zheng, Y.,
Johnson, L. R.,
and Tigyi, G.
(1997)
J. Clin. Invest.
100,
216-225[Medline]
[Order article via Infotrieve]
|
| 43.
|
Azuma, T.,
Witke, W.,
Stossel, T. P.,
Hartwig, J. H.,
and Kwiatkowski, D. J.
(1998)
EMBO J.
17,
1362-1370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Henning, S. W.,
Galandrini, R.,
Hall, A.,
and Cantrell, D. A.
(1997)
EMBO J.
16,
2397-2407[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Takano, H.,
Komuro, I.,
Oka, T.,
Shiojima, I.,
Hiroi, Y.,
Mizuno, T.,
and Yazaki, Y.
(1998)
Mol. Cell. Biol.
18,
1580-1589[Abstract/Free Full Text]
|
| 46.
|
Busca, R.,
Bertolotto, C.,
Abbe, P.,
Englaro, W.,
Ishizaki, T.,
Narumiya, S.,
Boquet, P.,
Ortonne, J. P.,
and Ballotti, R.
(1998)
Mol. Biol. Cell
9,
1367-1378[Abstract/Free Full Text]
|
| 47.
|
Jou, T. S.,
and Nelson, W. J.
(1998)
J. Cell Biol.
142,
85-100[Abstract/Free Full Text]
|
| 48.
|
Strutt, D. I.,
Weber, U.,
and Mlodzik, M.
(1997)
Nature
387,
292-295[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Bussey, H.
(1996)
Science
272,
224-225[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Hacker, U.,
and Perrimon, N.
(1998)
Genes Dev.
12,
274-284[Abstract/Free Full Text]
|
| 51.
|
Barrett, K.,
Leptin, M.,
and Settleman, J.
(1997)
Cell
91,
905-915[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Zheng, Y.,
Olson, M.,
Hall, A.,
Cerione, R.,
and Toksoz, D.
(1995)
J. Biol. Chem.
270,
9031-9034[Abstract/Free Full Text]
|
| 53.
|
Nobes, C. D.,
and Hall, A.
(1995)
Cell
81,
53-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Freedman, V. H.,
and Shin, S. I.
(1974)
Cell
3,
355-359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Temin, H. M.,
and Rubin, H.
(1958)
Virology
6,
669-688
|
| 56.
|
Cooper, G. M.
(1995)
Oncogenes
, 2nd Ed.
, pp. 69-84, Jones and Barlett, Boston
|
| 57.
|
Ron, D.,
Zannini, M.,
Lewis, M.,
Wickner, R. B.,
Hunt, L. T.,
Graziani, G.,
Tronick, S. R.,
Aaronson, S. A.,
and Eva, A.
(1991)
New Biol.
3,
372-379[Medline]
[Order article via Infotrieve]
|
| 58.
|
Stam, J. C.,
Michiels, F.,
van der Kammen, R. A.,
Moolenaar, W. H.,
and Collard, J. G.
(1998)
EMBO J.
17,
4066-4074[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Horii, Y.,
Beeler, J. F.,
Sakaguchi, K.,
Tachibana, M.,
and Miki, T.
(1994)
EMBO J.
13,
4776-4786[Medline]
[Order article via Infotrieve]
|
| 60.
|
Toksoz, D.,
and Williams, D. A.
(1994)
Oncogene
9,
621-628[Medline]
[Order article via Infotrieve]
|
| 61.
|
Chuang, T. H.,
Xu, X.,
Kaartinen, V.,
Heisterkamp, N.,
Groffen, J.,
and Bokoch, G. M.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10282-10286[Abstract/Free Full Text]
|
| 62.
|
Olson, M. F.
(1996)
J. Mol. Med.
74,
563-571[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Roux, P.,
Gauthier-Rouviere, C.,
Doucet-Brutin, S.,
and Fort, P.
(1997)
Curr. Biol.
7,
629-637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Khosravi-Far, R.,
Chrzanowska, W. M.,
Solski, P. A.,
Eva, A.,
Burridge, K.,
and Derr, C. J.
(1994)
Mol. Cell. Biol.
14,
6848-6857[Abstract/ |